Cancer patients are willing to undergo many tests in order to obtain an improved experimental treatment in clinical trials, according to a new study conducted by the Mayo Clinic, Research Institute for Translational Genomics and Health Organization of Scottsdale.According to the researchers, the willingness of patients to undergo various tests is a good sign for the future of personalized medicine, in which specific treatments are prescribed depending on the genetic pattern of DNA in cancer patients.
«This study - the first of its kind where patients themselves decide what tests and imaging techniques, they are willing to go through participation in clinical trials, the purpose of which is to develop an effective anti-cancer therapy.Patients were also asked about their reactions to the passage of the various analyzes and surveys "- said Raul Taybs, Doctor of Philosophy and Medicine, lead author of the study, recently published online prestigious scientific journal« Cancer »(Cancer), a physician-scientis
print publication of this study, we consider the willingness of patients to go pharmacodynamic and pharmacokinetic analyzes in the early stage of cancer tests, scheduled for July 15, 2011, the magazine «Cancer», published by the American Society of Cancer (American Cancer Society).
To learn more and to understand the molecular aspects of cancer, researchers need tumor samples and images obtained during the passage of such types of surveys are scanning with computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and other tests.The initial stage of clinical trials includes pharmacodynamic (effect of drugs on the body) and pharmacokinetics (the body's response to drugs) study.The authors performed a prospective study that examined the willingness of patients to undergo various tests and examinations, as well as the number of the latter, which patients will be able to endure.
«We have learned that, in general, patients are willing to undergo additional, unscheduled examinations in clinical trials," - says Dr. Taybs, former physician-researcher Clinical Research Services, which is a collaboration of the Institute of Translational Genomics and Health Organization, the Scottsdale CancerCenter.Virginia G. Piper in Scottsdale.
«This study will provide us with valuable information collected on real patients, and thus will be enough information for clinical research in an era when the molecular targeted therapy is becoming more and more accessible for us and our investigations are becoming more and more difficult"- says Dr. Taybs.
The study involved 61 patients - 22 women and 39 men - with cancer in the last stage.
They expressed full readiness to undergo tests and examinations required in the study.Patients are most readily expressed in passing urine, blood, ultrasound, X-ray, echocardiogram, CT scan and PET.The smallest willingness was expressed during the passage of the tumor and skin biopsies and MRI.However, the majority of patients, at least, were prepared to have to provide a sample, and often two samples of tumor biopsies for the purposes of the study.
«The information is important for us because we will be able to conduct clinical trials for which, if necessary, will be able to collect additional samples of tumor biopsies of patients.But first we need to give an accurate estimate on the number of biopsy samples, which we need, and what molecular tests we conduct with the data samples, "- says MD Mitesh J. Borad, deputy head of the initial stage of drug development at the Mayo Clinic in Arizona, andthe main author of the study.
The study found that the inconvenience and prior negative experience during the passage of invasive tests, such as skin biopsy, had little negative impact on the willingness of patients to go through these tests again.Interestingly, patients with higher education and insurance coverage have shown more willingness to pass the required tests.
According to Dr. Taybsa, who is also deputy head of the Program for the Study of acute and chronic leukemia, the Mayo Clinic, this study can serve as a basis for further studies leading to the development of favorable patient clinical trials based on biomarkers of cancer.
«The results of this study will serve as a basis for further scientific work," - says Dr. Taybs, stressing the need for such studies, the center of which are the interests of the patient, as well as the need in communicating to patients information about their treatment, including the goals of clinical research."I think the patients themselves must inform us of their willingness to undergo a particular type of analysis.We need to communicate more with patients.It is very important".